Functional Recovery After Wharton’s Jelly-Derived Mesenchymal Stem Cell Administration in a Patient with Traumatic Brain Injury: A Pilot Study

The efficacy of treatment with SCT was assessed with cranial magnetic resonance imaging (MRI), computed tomography (CT) screening, and electroencephalography (EEG).CONCLUSION: SCT can have a promising future as a medical approach in recurre

📌 3 Key Takeaways

🎯

Objective & Hypothesis:AIM: To introduce a traumatic brain injury (TBI) patient who underwent stem cell transplantation (SCT) in order to minimize the remaining injury deficiencies.

📊

Key Findings & Data:MATERIAL and METHODS: This study included a 29 years old male who had TBI resulting from a vehicle accident which took place one and a half years ago.

💡

Conclusion & Impact:The efficacy of treatment with SCT was assessed with cranial magnetic resonance imaging (MRI), computed tomography (CT) screening, and electroencephalography (EEG).CONCLUSION: SCT can have a promising future as a medical approach in recurre

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Özet

AIM: To introduce a traumatic brain injury (TBI) patient who underwent stem cell transplantation (SCT) in order to minimize the remaining injury deficiencies. MATERIAL and METHODS: This study included a 29 years old male who had TBI resulting from a vehicle accident which took place one and a half years ago. The participant received six doses of intrathecal, intramuscular, and intravenous transplantation of Wharton’s jellv-derived mesenchymal stem cells (WJ-MSCs) at a goal dose of 1xl06 / kg respectively for each route of administration for six months.RESULTS: No important negative effects were reported. The patients’ speech, cognitive, memory and fine motor skills were improved. The efficacy of treatment with SCT was assessed with cranial magnetic resonance imaging (MRI), computed tomography (CT) screening, and electroencephalography (EEG).CONCLUSION: SCT can have a promising future as a medical approach in recurre

🔖

Cite This Article

KABATAŞ, S., KABATAŞ, S., SEZEN, G. B., KAPLAN, N., SAVRUNLU, E. C., CETIN, E., DİREN, F., KARAÖZ, E. (2020). Functional Recovery After Wharton’s Jelly-Derived Mesenchymal Stem Cell Administration in a Patient with Traumatic Brain Injury: A Pilot Study. Turkish Neurosurgery, Cilt: 30 - Sayı: 6, 914–922. https://ajindex.com/articles/404303

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (1)

Fischer UM, Harting MT, Jimenez F, Monzon-Posadas WO, Xue, H: Pulmonary passage is a major obstacle for intravenous stem cell delivery: The pulmonary first-pass effect. Stem Cells Dev 18:683-692, 2009 2. Galindo LT, Filippo TRM., Semedo P, Ariza CB, Moreira CM, Camara NOS, Porcionatto MA: Mesenchymal stem cell therapy modulates the inflammatory response in experimental traumatic brain injury. Neurol Res Int 2011:564089, 2011 3. Gang LI, Yang Y, Dong H, Lin L: The research progress of mesenchymal stem cells in the treatment of traumatic brain injury. Turk Neurosurg 28(5):696-702, 2018 4. Ghajar, J: Traumatic brain injury. Lancet 356:923-929, 2000 5. Heegaard W, Biros M: Traumatic brain injury. Emerg Med Clin North Am 25:655-678, 2007 6. Hlebokazov F, Dakukina T, Ihnatsenko S, Kosmacheva S, Potapnev M, Shakhbazau A, Goncharova N, Makhrov M, Korolevich P, Misyuk N, Dakukina V, Shamruk I, Slobina E, Marchuk S: Treatment of refractory epilepsy patients with autologous mesenchymal stem cells reduces seizure frequency: An open label study. Adv Med Sci 62(2):273‐279, 2017 7. Kabatas S, Civelek E, İnci C, Yalcinkaya EY, Gunel G, Kir G, Albayrak E, Ozturk E, Adas G, Karaoz E: Wharton’s jellyderived mesenchymal stem cell transplantation in a patient with hypoxic-ischemic encephalopathy: A pilot study. Cell Transplant 27(10):1425-1433, 2018 8. Kamelska-Sadowska AM, Wojtkiewicz J, Kowalski IM: Review of the current knowledge on the role of stem cell transplantation in neurorehabilitation. Biomed Res Int 25:3290894, 2019 9. Kim JJ, Gean AD: Imaging for the diagnosis and management of traumatic brain injury. Neurotherapeutics 8:39-53, 2011 10. Langlois JA, Rutland-Brown W, Wald MM: The epidemiology and impact of traumatic brain injury: A brief overview. J Head Trauma Rehabil 21:375-378, 2006 11. Liao G, Harting M, Hetz R, Walker PA, Do SKS, Corkins CJ, Hughes TG, Jimenez F, Kosmach SC, Day MC, Tsao KJ, Lee DA, Worth LL, Baumgartner JA, Cos CS: Autologous bone marrow mononuclear cells reduce therapeutic intensity for severe traumatic brain injury in children. Pediatr Crit Care Med 16:245-255, 2015 12. Maas AI, Stocchetti N, Bullock R: Moderate and severe traumatic brain injury in adults. Lancet Neurol 7:728-741, 2008 13. Mahmood A, Lu D, Lu M, Chopp M: Treatment of traumatic brain injury in adult rats with intravenous administration of human bone marrow stromal cells. J Neurosurg 53:693-702, 2003 14. McKintosh T: Novel pharmacologic therapies in the treatment of experi